2-Isopropyl-4-methyl thiazole | CAS:15679-13-7

We serve 2-Isopropyl-4-methyl thiazole CAS:15679-13-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Isopropyl-4-methyl thiazole

Chemical Name:2-Isopropyl-4-methyl thiazole
CAS.NO:15679-13-7
Synonyms:2-Isopropyl-4-methyl thiazole
4-methyl-2-propan-2-yl-1,3-thiazole
2-Isopropyl-4-Methylthiazole
 
Physical and Chemical Properties:
Density 1.0±0.1 g/cm3
Boiling Point 180.9±9.0 °C at 760 mmHg
Molecular Formula C7H11NS
Molecular Weight 141.234
Flash Point 58.3±0.0 °C
 
Specification:
Appearance:Colorless to pale yellow liquid
Assay:≥99.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Flavors and fragrances intermediate



Contact us for information like 2-Isopropyl-4-methyl thiazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Isopropyl-4-Methylthiazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-methyl-2-propan-2-yl-1,3-thiazole Use and application,2-Isopropyl-4-Methylthiazole technical grade,usp/ep/jp grade.


Related News: Since first being reported in the city of Wuhan, where it is believed to have originated at a seafood market, the virus has not provoked unusual symptoms in people who have been diagnosed.3-phenoxybenzaldehyde cyanohydrin manufacturer According to the business type, it can be divided into non-CMO business of APIs and intermediates and CMO business of APIs and intermediates.4-bromo-3-fluoropyridine supplier As you can see, a considerable number of staff is involved in the production phase until an API is finally manufactured.4-hydroxy-2-quinolone vendor In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of “predictable” clinical value for life-threatening diseases for which effective treatment is not immediately available.Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.